1 / 38
Javier Puente, MD, PhD
Director of the Institute of Oncology
Associate Professor of Medicine
Medical Oncology Department
GU Cancer Unit
Hospital Clínico San Carlos, Madrid, Spain
Complutense University of Madrid, Spain
Tivozanib: ¿hace falta un
nuevo Tki en 1L de RCC?